162848-16-0

Basic information

• Product Name: 4-(1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID
• Synonyms: BUTTPARK 95\50-80;ART-CHEM-BB B022049;AKOS B022049;4-[1,2,4]TRIAZOL-1-YL-BENZOIC ACID;4-(1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID;RARECHEM AL BE 1325;OTAVA-BB BB7018780039;4-[1,2,4]TRIAZOL-1-YL-BENZOIC ACID 95%
• CAS NO: 162848-16-0
• Molecular Formula: C₉H₇N₃O₂
• Molecular Weight: 189.17
• Product Categories: Acids and Derivatives;Heterocycles
• Mol File: 162848-16-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 318 °C
• Boiling Point: 424.1 °C at 760 mmHg
• Flash Point: 210.3 °C
• Appearance: white crystal powder
• Density: 1.39 g/cm³
• Vapor Pressure: 6E-08mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID(162848-16-0)
• EPA Substance Registry System: 4-(1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID(162848-16-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 162848-16-0(Hazardous Substances Data)

Usage

General Description

4-(1H-1,2,4-Triazol-1-yl)benzoic acid is a chemical compound that is categorised under organotriazoles - compounds that contain a five-member aromatic ring consisting of two carbon atoms and three nitrogen atoms. This particular compound is noted for its involvement in the formation of other complex compounds, often serving as a starting material or intermediary in certain organic synthesis processes. It has one acidic functional group (carboxylic acid) and one heterocyclic aromatic ring (1,2,4-triazole). There is limited information available regarding its applications or proposed uses, but as a derivative of benzoic acid, it may find potential use in a wide variety of chemical, pharmaceutical, and material science applications. The exact properties like toxicity, reactivity, and environmental impact would depend on the specific conditions and details of those applications.

InChI:InChI=1/C9H7N3O2/c13-9(14)7-1-3-8(4-2-7)12-6-10-5-11-12/h1-6H,(H,13,14)/p-1

Upstream product

• 143426-48-6 ethyl 4-(1,2,4-triazol-1-yl)benzoate 
• 288-88-0 1,2,4-Triazole 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 
• 27996-86-7 4-(1H-1,2,4-triazol-1-yl)benzaldehyde 

Downstream Products

• 812639-95-5 methyl-phenyl-carbamic acid 5-(4-[1,2,4]triazol-1-yl-benzoylamino)-pyridin-2-yl ester 
• 162848-17-1 4-(1H-1,2,4-triazol-1-yl)benzoyl chloride 
• 1267504-45-9 N-[2,6-dibromo-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-phenyl]-4-(1H-1,2,4-triazol-1-yl)benzamide 
• 1354554-87-2 4-[1,2,4]triazol-1-yl-benzoic acid 3-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-ylcarbamoyl)-benzylamide 
• 1353548-26-1 [(Sn(n-Bu)2)4(4-triazolylbenzoate)2O₂(MeO)2] 
• 1353548-23-8 [SnPh₃(4-triazolylbenzoate)] 
• 1500076-46-9 (R)-tert-butyl (4-(4-(1H-1,2,4-triazol-1-yl)benzamido)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate 

Relevant articles and documents

Noncentrosymmetric organic solid and its zinc coordination polymer with diamonded network prepared from an ionothermal reaction: Syntheses, crystal structures, and second-order nonlinear optics properties

An organic ligand 4-(1,2,4-triazol-1-yl) benzoic acid (Htzbc) with a nonlinear optical (NLO) chromophore has been synthesized. Reaction of Zn(NO 3)2 with Htzbc ligand in 1-n-butyl-3-methylimidazolium tetrafluoroborate ionic liquid af

New compounds, pharmaceutical compositions and uses thereof

The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.